BerganKDV Wealth Management’s Rigel Pharmaceuticals RIGL Stock Holding History

BerganKDV Wealth Management’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$12.9K	Hold	1,000	–	–	﹤0.01%	531
2023 Q1	$13.2K	Hold	1,000	–	–	﹤0.01%	564
2022 Q4	$15K	Hold	1,000	–	–	﹤0.01%	524
2022 Q3	$12K	Hold	1,000	–	–	﹤0.01%	555
2022 Q2	$11K	Hold	1,000	–	–	﹤0.01%	579
2022 Q1	$30K	Hold	1,000	–	–	﹤0.01%	464
2021 Q4	$27K	Buy	1,000 +350	+54%	+$10.6K	﹤0.01%	505
2021 Q3	$24K	Hold	650	–	–	﹤0.01%	503
2021 Q2	$28K	Hold	650	–	–	﹤0.01%	472
2021 Q1	$22K	Hold	650	–	–	﹤0.01%	472
2020 Q4	$23K	Hold	650	–	–	﹤0.01%	452
2020 Q3	$16K	Hold	650	–	–	﹤0.01%	453
2020 Q2	$12K	Buy	650 +400	+160%	+$7.2K	﹤0.01%	520
2020 Q1	$4K	Hold	250	–	–	﹤0.01%	628
2019 Q4	$5K	Hold	250	–	–	﹤0.01%	627
2019 Q3	$5K	Hold	250	–	–	﹤0.01%	564
2019 Q2	$7K	Hold	250	–	–	﹤0.01%	556
2019 Q1	$6K	Hold	250	–	–	﹤0.01%	578
2018 Q4	$6K	Hold	250	–	–	﹤0.01%	533
2018 Q3	$8K	Hold	250	–	–	﹤0.01%	516
2018 Q2	$7K	Buy	+250	New	+$8.9K	﹤0.01%	541

Other funds holding RIGL

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BerganKDV Wealth Management's RIGL Position: Q2 2023 in Review

BerganKDV Wealth Management held its Rigel Pharmaceuticals (RIGL) position steady in Q2 2023 at 1,000 shares worth $12.9K. The position accounts for ﹤0.01% of the portfolio, ranked #531.

BerganKDV Wealth Management first reported a position in RIGL in Q2 2018 and has held it in 21 quarters since. The position peaked at $30K in Q1 2022. 118 funds tracked by Wall St. Rank hold RIGL as of Q2 2023.

BerganKDV Wealth Management held 1,000 shares of Rigel Pharmaceuticals worth $12.9K as of Q2 2023.
BerganKDV Wealth Management left its Rigel Pharmaceuticals share count unchanged in Q2 2023.
Rigel Pharmaceuticals made up ﹤0.01% of BerganKDV Wealth Management's portfolio in Q2 2023, its #531 holding.
BerganKDV Wealth Management first reported a position in Rigel Pharmaceuticals in Q2 2018 and has held it in 21 quarters since.
BerganKDV Wealth Management's Rigel Pharmaceuticals position peaked at $30K in Q1 2022.
118 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2023.

Based on BerganKDV Wealth Management's 13F filing for Q2 2023, filed 24 Jul 2023.